This study aimed to evaluate the prognostic value of KIT and PDGFRA mutation subtypes in a large‐scale cohort of Chinese patients with GIST after treatment with the current therapy including surgery and imatinib treatment. The gene discussed is PDGFRA; the disease is gastrointestinal stromal tumor.